NEWS & ACCOMPLISHMENTS
Program News
Griffithsin-based Rectal Microbicides for PREvention of Viral ENTry (PREVENT). http://grantome.com/grant/NIH/U19-AI113182-04
$14.7 million NIH grant to University of Louisville in collaboration with prof Broliden. https://ki.se/en/news/147-million-grant-to-research-collaboration-with-professor-broliden
Can the tobacco plant be the key to HIV prevention? http://uoflnews.com/post/uofltoday/can-the-tobacco-plant-be-the-key-to-hiv-prevention/
Conference Presentations
Tusé D, Palmer KE, et al. (2017). Progress of Griffithsin development for first-in-human clinical trial (Plenary Lecture). Plant-Based Vaccines, Antibodies and Biologics (PBVAB), 5-7 June, Albufeira, Portugal.
Microbicide Trials Network Annual Meeting (2016), Bethesda, MD. Palmer KE et al. "PREVENT Rectal Microbicide Program." http://www.mtnstopshiv.org/sites/default/files/attachments/Palmer.pdf
Publications
Fuqua JL, Wanga V, Palmer KE (2015). Improving the large-scale purification of the HIV microbicide, griffithsin. BMC Biotechnol 15:12. doi: 10.1186/s12896-015-0120-5
Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, Montefiori DC, Vojdani F, McCormick AA, O'Keefe BR, Palmer KE (2014). Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrobial Agents and Chemother 58(1): 120-127. doi: 10.1128/AAC.01407-13
Nixon B, Stefanidou M, Mesquita PM, Fakioglu E, Segarra T, Rohan L, Halford W, Palmer KE, Herold BC (2013). Griffithsin prevents genital herpes in mice by preventing cell to cell spread. J Virol 87(11): 6257-69. doi: 10.1128/JVI.00012-13
Férir G, Huskens D, Palmer KE, Boudreaux DM, Swanson MD, Markovitz DM, Balzarini J, Schols D (2012). Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV Type 1, HIV Type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains. AIDS Res Human Retrovir 28(11):1513-23. doi: 10.1089/AID.2012.0026
Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, Leroux-Roels G, Palmer KE, Dubuisson J (2011). Griffithsin has antiviral activity against hepatitis C virus. Antimicrobial Agents and Chemother 55: 5159-67. doi: 10.1128/AAC.00633-11
Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, Walter W, Walker JM, Matoba N, O'Keefe BR, Palmer KE (2011). Investigation of Griffithsin’s interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS ONE 6(8): e22635. doi: 10.1371/journal.pone.0022635
Férir G, Palmer KE, Shols D (2011). Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 417(2):253-8. doi: 10.1016/j.virol.2011.07.004
Banerjee K, Michael E, Eggink D, van Montfort T, Lasnik AB, Palmer KE, Sanders RW, Moore JP, Klasse PJ (2012). Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. AIDS Res Hum Retroviruses 28(2):206-14. doi: 10.1089/aid.2011.0101
O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, Palmer KE, Barnett BW, Meyerholz DK, Wohlford-Lenane CL, McCray PB Jr (2010). Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virology 84(5):2511-21. doi: 10.1128/JVI.02322-09
O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE (2009). Scalable manufacture of HIV entry inhibitor Griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Nat Acad Sciences USA 106: 6099-104. doi: 10.1073/pnas.0901506106
Emau P, Tian B, O'Keefe BR, Mori T, McMahon JB, Palmer KE, Jiang Y, Bekele G, Tsai CC (2007). Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol. 2007; 36(4-5):244-53. doi: 10.1111/j.1600-0684.2007.00242.x
Ziółkowska NE, Shenoy SR, O'Keefe BR, McMahon JB, Palmer KE, Dwek RA, Wormald MR, Wlodawer A (2007). Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins (2007); 67(3):661-70. doi: 10.1002/prot.21336
Ziółkowska NE, O'Keefe BR, Mori T, Zhu C, Giomarelli B, Vojdani F, Palmer KE, McMahon JB, Wlodawer A (2006). Domain-swapped structure of the potent antiviral protein griffithsin and its mode of carbohydrate binding. Structure 14(7):1127-35. doi: 10.1016/j.str.2006.05.017